HaplnScience, Inc. is a bio-venture company established in late 2018
with the aim to develop fundamental treatments for aging-related diseases.
We will contribute to the health and well-being of humankind by restoring the damaged or
degenerated tissue with aging through research on the unique mechanism of ‘rhHAPLN1’
and its development as a breakthrough anti-aging therapy.

We are developing disease-modifying therapies that leverage recombinant human HAPLN1 (rhHAPLN1)a protein with tissue-regenerative and rejuvenating activity?to fundamentally treat chronic obstructive pulmonary disease (COPD) and osteoarthritis (OA). Our COPD candidate (HS-401) targets emphysema-associated disease and is designed to regenerate lung tissue and restore pulmonary function; the preclinical program has been completed. This program pursues what has long been considered unattainable: a curative approach to COPD. Our osteoarthritis candidate (HS-101) is intended to achieve true disease modification by repairing and structurally restoring cartilage, synovium, and subchondral bone; most preclinical studies have now been completed.